Latest Bio-Path Holdings (BPTH) Headlines Bio
Post# of 62
Posted On: 03/09/2014 4:14:08 AM
Latest Bio-Path Holdings (BPTH) Headlines
Bio-Path Holdings to trade common stock on NASDAQ Capital Market
M2 - Thu Mar 06, 5:59AM CST
Biotechnology company Bio-Path Holdings (Other OTC:BPTH) stated on Wednesday that its common stock will be listed in the NASDAQ Capital Market following approval.
Bio-Path Holdings Announces Uplisting to the NASDAQ Capital Market
Business Wire - Wed Mar 05, 1:19PM CST
Bio-Path Holdings, Inc., (OTCQX: BPTH) ("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that its shares of common stock have been approved for uplisting to the NASDAQ Capital Market. Effective Monday, March 10, 2014, the stock will trade on the NASDAQ Capital Market under the symbol BPTH.
Global RNAi Drug Delivery Market 2014-2018: Read What's Trending
M2 - Wed Feb 19, 12:15PM CST
Research and Markets (http://www.researchandmarkets.com/research/kv93pj/global_rnai_drug) has announced the addition of the "Global RNAi Drug Delivery Market 2014-2018" report to their offering. The analysts forecast the Global RNAi Drug Delivery market to grow at a CAGR of 21.80 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase in RNA therapeutic development. The Global RNAi Drug Delivery market has also been witnessing some key technological advancements. However, the targeted delivery of RNA molecules is expected to pose a challenge to the growth of this market. Key vendors dominating this space are Alnylam Pharmaceuticals Inc., Isis Pharmaceuticals, Inc.,Merck & Co. Inc., and Tekmira Pharmaceuticals Corp. Other vendors mentioned in the report are Access Pharmaceuticals Inc., Calondo Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Marina Biotech Inc., PhaseRx Inc., Quark Pharmaceuticals Inc., RXi Pharmaceuticals Corp., Silence Therapeutics plc, Sirnaomics Inc., Tacere Therapeutics Inc., and Traversa Therapeutics Inc. Commenting on the report, an analyst from the team said: Major advances in RNAi drug delivery are aimed at developing better delivery agents with excellent efficacy and the ability to target specific cells. For example, Bio-Path Holdings Inc. developed systemic delivery of antisense, small interfering RNA, and hydrophobic small molecules for treatment of various diseases using its neutral lipid drug delivery technology (neutral liposome). Similarly, Inovio's skin electroporation technology was used for the successful delivery of small interfering RNA molecules to skin in animal studies. Thus, technological innovations would further contribute to the growth of the Global RNAi Drug Delivery market. According to the report, one of the major drivers in this market is the increase in RNA therapeutic development. Therapeutic benefits greatly depend on the efficiency of the RNA delivery to specific diseased cells. This factor is the key to the development of RNAi drug delivery technologies and the market associated with it. For more information visit http://www.researchandmarkets.com/research/kv..._rnai_drug About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Latest Thyroid Cancer Pipeline Review
M2 - Tue Jan 28, 10:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/zmc3df/thyroid_cancer) has announced the addition of the "Thyroid Cancer - Pipeline Review, H2 2013" report to their offering. 'Thyroid Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thyroid Cancer. Scope - A snapshot of the global therapeutic scenario for Thyroid Cancer. - A review of the Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Thyroid Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Bio-Path Holdings, Inc. - Eisai Co., Ltd. - Bayer AG - Bionomics Limited - Azaya Therapeutics Incorporated - Vascular Biogenics Ltd. - Biovista Inc. - Trophogen, Inc. - centrose llc - Ecrins Therapeutics SAS For more information visit http://www.researchandmarkets.com/research/zm...oid_cancer
Bio-Path Holdings Inc expects USD10m in registered direct offering
M2 - Fri Jan 17, 10:38AM CST
Biotechnology company Bio-Path Holdings Inc (-OTC Markets:BPTH) said on Thursday that it expects to raise about USD10.0m from the sale of units at USD3.00 per unit in a registered direct offering .
Bio-Path Holdings, Inc. to Raise $10 Million in Registered Direct Offering
Business Wire - Thu Jan 16, 7:00AM CST
Bio-Path Holdings, Inc. (OTCQX: BPTH) (Bio-Path), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, announced today that it is raising approximately $10.0 million in a registered direct offering at a price of $3.00 per unit. The entire offering is being sold to two dedicated healthcare funds that are managed by Sabby Management. Each Unit shall consist of one share of Bio-Path common stock, and a warrant to purchase one half (0.5) of a share of Bio-Path common stock. The common stock and warrants shall be immediately separable. The warrants will be exercisable immediately, have a term of five years and an exercise price of $4.74 per share of common stock. After placement agent fees and estimated offering expenses, the Company expects to receive net proceeds of approximately $9.3 million. The offering is expected to close on or about January 22, 2014, subject to customary closing conditions.
Bio-Path Holdings to Present at the Biotech Showcase(TM) 2014 Conference
Business Wire - Mon Jan 06, 9:59AM CST
Bio-Path Holdings, Inc. (OTCQX: BPTH) ("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that Peter Nielsen, President and Chief Executive Officer, will present a company overview at the Biotech Showcase(TM) 2014 Conference in San Francisco, Calif., on Wednesday, January 15, 2014 at 8:00 a.m. Pacific Time.
Preliminary Results from Bio-Path Holdings' Phase I Clinical Trial Presented at the Annual Meeting of the American Society of Hematology (ASH) in New Orleans
Business Wire - Mon Dec 09, 10:20AM CST
Bio-Path Holdings, Inc., (OTCQX: BPTH) ("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, announced that Dr. Jorge Cortes, deputy chair and professor of medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, presented Phase I data from Bio-Path's clinical trial evaluating its lead product candidate, Liposomal Grb-2 (BP-100-1.01), in hematological cancers at the 55th Annual Meeting of the American Society of Hematology (ASH) in New Orleans.
Bio-Path Holdings Reports Third Quarter 2013 Operational and Financial Results
Business Wire - Fri Nov 15, 12:30PM CST
Bio-Path Holdings, Inc., (OTCQX: BPTH) ("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the third quarter ended September 30, 2013.
Data from Bio-Path Holdings Phase I Clinical Trial in Hematological Cancers to be Presented at American Society of Hematology Annual Meeting
Business Wire - Thu Nov 07, 3:03PM CST
Bio-Path Holdings, Inc. (OTCQX: BPTH) ("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that there will be a poster presentation by Dr. Jorge Cortes, deputy chair and professor of medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, at the 55th Annual Meeting of the American Society of Hematology (ASH) in New Orleans. The poster will highlight an assay that was developed to measure inhibition of the disease target protein Grb-2 in patients' peripheral blood samples from the ongoing Phase I trial evaluating the Company's lead compound, Liposomal Grb-2 antisense oligonucleotides in hematological cancers.
Bio-Path Holdings Inc retains Maxim Group LLC as investment banking firm
M2 - Fri Sep 20, 8:00AM CDT
Biotechnology company Bio-Path Holdings Inc (OTC Markets:BPTH) reported on Thursday that it has hired Maxim Group LLC as its financial advisor again for its next phase.
Bio-Path Holdings, Inc. Retains Investment Banking Firm Maxim Group LLC
Business Wire - Thu Sep 19, 8:30AM CDT
Bio-Path Holdings, Inc., (OTCQX: BPTH) ("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has retained Maxim Group LLC, as a financial advisor. Maxim will focus on assisting Bio-Path in its strategies for maximizing shareholder value through its full scope of investment banking services.
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w6k5cg/acute_myelocytic) has announced the addition of the "Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2013" report to their offering. 'Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). Scope - A snapshot of the global therapeutic scenario for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). - A review of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Genzyme Corporation Johnson & Johnson Boehringer Ingelheim GmbH F. Hoffmann-La Roche Ltd. Amgen Inc. Sanofi-Aventis AstraZeneca PLC Eli Lilly and Company GlaxoSmithKline plc Seattle Genetics, Inc. Genentech, Inc. Gilead Sciences, Inc. Daiichi Sankyo Company, Ltd medac GmbH Merck & Co., Inc. Gamida Cell Ltd. Generex Biotechnology Corporation Plexxikon Inc. BioLineRx, Ltd. Bio-Path Holdings, Inc. Millennium Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/w6...myelocytic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Head And Neck Cancer - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5stc2x/head_and_neck) has announced the addition of the "Head And Neck Cancer - Pipeline Review, H2 2013" report to their offering. 'Head And Neck Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Head And Neck Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Head And Neck Cancer. Scope - A snapshot of the global therapeutic scenario for Head And Neck Cancer. - A review of the Head And Neck Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Head And Neck Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Boehringer Ingelheim GmbH Eli Lilly and Company Inovio Biomedical Corporation Gilead Sciences, Inc. GenVec, Inc. Piramal Healthcare Limited Bio-Path Holdings, Inc. Millennium Pharmaceuticals, Inc. Novartis AG Daewoong Pharmaceutical Co., Ltd. Taiho Pharmaceutical Co., Ltd. Takara Holdings Inc. Cell Therapeutics, Inc. CEL-SCI Corporation Advaxis, Inc. Bionomics Limited Northwest Biotherapeutics, Inc. Oncolytics Biotech Inc. Curis, Inc. Transgene SA Panacea Biotec Limited and many more.... For more information visit http://www.researchandmarkets.com/research/5s...d_and_neck About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snxwsx/acute_lymphocytic) has announced the addition of the "Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2013" report to their offering. 'Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). Scope - A snapshot of the global therapeutic scenario for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). - A review of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Amgen Inc. Sanofi-Aventis Seattle Genetics, Inc. MedImmune LLC medac GmbH Gamida Cell Ltd. Bio-Path Holdings, Inc. Millennium Pharmaceuticals, Inc. Novartis AG Pfizer Inc. Incyte Corporation 4SC AG IMMUNOMEDICS, INC Ariad Pharmaceuticals, Inc. OncoVista Innovative Therapies, Inc. Jazz Pharmaceuticals, Inc. Portola Pharmaceuticals, Inc. Mundipharma International Limited MorphoSys AG Lipoxen PLC and many more... For more information visit http://www.researchandmarkets.com/research/sn...ymphocytic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Myelodysplastic Syndrome - Pipeline Review, H2 2013
M2 - Mon Sep 09, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7p96jv/myelodysplastic) has announced the addition of the "Myelodysplastic Syndrome - Pipeline Review, H2 2013" report to their offering. 'Myelodysplastic Syndrome - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Myelodysplastic Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome. Scope - A snapshot of the global therapeutic scenario for Myelodysplastic Syndrome. - A review of the Myelodysplastic Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Myelodysplastic Syndrome pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Amgen Inc. Athersys, Inc. GlaxoSmithKline plc Daiichi Sankyo Company, Ltd medac GmbH Merck & Co., Inc. Dainippon Sumitomo Pharma Co., Ltd. Gamida Cell Ltd. Bio-Path Holdings, Inc. Millennium Pharmaceuticals, Inc. Novartis AG Pfizer Inc. Sunesis Pharmaceuticals, Inc. SuperGen, Inc. Teva Pharmaceutical Industries Limited Cyclacel Pharmaceuticals Inc. Celgene Corporation Incyte Corporation 4SC AG Celldex Therapeutics, Inc. Marshall Edwards, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/7p...dysplastic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bio-Path Holdings Reports Second Quarter 2013 Operational and Financial Results
Business Wire - Thu Aug 15, 8:30AM CDT
Bio-Path Holdings, Inc., (OTCQX: BPTH) ("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the second quarter ended June 30, 2013.
Bio-Path Holdings' Liposomal Delivery Technology Achieves Major Milestone in Development of Antisense Therapeutics
Business Wire - Fri Aug 09, 8:30AM CDT
Bio-Path Holdings, Inc. (OTCQX: BPTH) ("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that a scientific assay has confirmed that its lead product candidate BP-100-1.01 (Liposomal Grb-2) inhibits the disease-causing target protein in patients with blood cancers. The assay was applied to patient samples taken from Bio-Path's Phase I clinical trial which is evaluating Liposomal Grb-2 in blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS). This discovery is a significant milestone in the development of Bio-Path's liposomal delivery technology and the specific data from this testing is planned to be reviewed at the Annual Society of Hematology (ASH) meeting in December by Jorge Cortes, M.D., Professor and Deputy Chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center (MD Anderson Cancer Center).
Therapeutic Report for Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
M2 - Tue Aug 06, 5:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5sqnpw/acute_lymphocytic) has announced the addition of the "Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2012" report to their offering. This report provides an overview of the acute lymphocytic leukemia therapeutic pipeline. It provides information on the therapeutic development for acute lymphocytic leukemia complete with latest updates, and special features on late-stage and discontinued projects. The document is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for acute lymphocytic leukemia. - A review of the acute lymphocytic leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the acute lymphocytic leukemia pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for acute lymphocytic leukemia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players with the most promising pipeline. - Devise corrective measures for pipeline projects by understanding acute lymphocytic leukemia pipeline depth and focus of acute lymphocytic leukemia therapeutics. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Acute Lymphocytic Leukemia Overview Therapeutics Development An Overview of Pipeline Products for Acute Lymphocytic Leukemia Companies Involved in Acute Lymphocytic Leukemia Therapeutics Development Drug Profiles Featured News & Press Releases Appendix Companies Mentioned (40) Including: - 4SC AG - Ariad Pharmaceuticals - Bio-Path Holdings - Bristol-Myers Squibb Company - CanBas Co - Exelixis - F. Hoffmann-La Roche - Genzyme Corporation - Hana Biosciences - Incyte Corporation - Jazz Pharmaceuticals - KaloBios Pharmaceuticals - Lentigen Corporation - Millennium Pharmaceuticals - MorphoSys AG - Mundipharma International - Novartis AG - Onconova Therapeutics - Oryzon - Pfizer - Proacta - Sigma-Tau Pharmaceuticals - SuperGen - SymbioTec GmbH - Threshold Pharmaceuticals - TopoTarget A/S - Tragara Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/5s...ymphocytic
Bio-Path Holdings Initiates Development of Liposomal Grb-2 for Triple Negative and Inflammatory Breast Cancers
Business Wire - Mon Jul 22, 8:30AM CDT
Bio-Path Holdings, Inc., (OTCQX:BPTH) ("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it is initiating preclinical testing of its lead product candidate, BP-100-1.01 (Liposomal Grb-2), into two additional indications: triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates. Bio-Path is currently evaluating Liposomal Grb-2 in a Phase I clinical trial as a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS). The clinical trial and research is being conducted at The University of Texas MD Anderson Cancer Center (MD Anderson Cancer Center).
Bio-Path Holdings to trade common stock on NASDAQ Capital Market
M2 - Thu Mar 06, 5:59AM CST
Biotechnology company Bio-Path Holdings (Other OTC:BPTH) stated on Wednesday that its common stock will be listed in the NASDAQ Capital Market following approval.
Bio-Path Holdings Announces Uplisting to the NASDAQ Capital Market
Business Wire - Wed Mar 05, 1:19PM CST
Bio-Path Holdings, Inc., (OTCQX: BPTH) ("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that its shares of common stock have been approved for uplisting to the NASDAQ Capital Market. Effective Monday, March 10, 2014, the stock will trade on the NASDAQ Capital Market under the symbol BPTH.
Global RNAi Drug Delivery Market 2014-2018: Read What's Trending
M2 - Wed Feb 19, 12:15PM CST
Research and Markets (http://www.researchandmarkets.com/research/kv93pj/global_rnai_drug) has announced the addition of the "Global RNAi Drug Delivery Market 2014-2018" report to their offering. The analysts forecast the Global RNAi Drug Delivery market to grow at a CAGR of 21.80 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase in RNA therapeutic development. The Global RNAi Drug Delivery market has also been witnessing some key technological advancements. However, the targeted delivery of RNA molecules is expected to pose a challenge to the growth of this market. Key vendors dominating this space are Alnylam Pharmaceuticals Inc., Isis Pharmaceuticals, Inc.,Merck & Co. Inc., and Tekmira Pharmaceuticals Corp. Other vendors mentioned in the report are Access Pharmaceuticals Inc., Calondo Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Marina Biotech Inc., PhaseRx Inc., Quark Pharmaceuticals Inc., RXi Pharmaceuticals Corp., Silence Therapeutics plc, Sirnaomics Inc., Tacere Therapeutics Inc., and Traversa Therapeutics Inc. Commenting on the report, an analyst from the team said: Major advances in RNAi drug delivery are aimed at developing better delivery agents with excellent efficacy and the ability to target specific cells. For example, Bio-Path Holdings Inc. developed systemic delivery of antisense, small interfering RNA, and hydrophobic small molecules for treatment of various diseases using its neutral lipid drug delivery technology (neutral liposome). Similarly, Inovio's skin electroporation technology was used for the successful delivery of small interfering RNA molecules to skin in animal studies. Thus, technological innovations would further contribute to the growth of the Global RNAi Drug Delivery market. According to the report, one of the major drivers in this market is the increase in RNA therapeutic development. Therapeutic benefits greatly depend on the efficiency of the RNA delivery to specific diseased cells. This factor is the key to the development of RNAi drug delivery technologies and the market associated with it. For more information visit http://www.researchandmarkets.com/research/kv..._rnai_drug About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Latest Thyroid Cancer Pipeline Review
M2 - Tue Jan 28, 10:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/zmc3df/thyroid_cancer) has announced the addition of the "Thyroid Cancer - Pipeline Review, H2 2013" report to their offering. 'Thyroid Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thyroid Cancer. Scope - A snapshot of the global therapeutic scenario for Thyroid Cancer. - A review of the Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Thyroid Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Bio-Path Holdings, Inc. - Eisai Co., Ltd. - Bayer AG - Bionomics Limited - Azaya Therapeutics Incorporated - Vascular Biogenics Ltd. - Biovista Inc. - Trophogen, Inc. - centrose llc - Ecrins Therapeutics SAS For more information visit http://www.researchandmarkets.com/research/zm...oid_cancer
Bio-Path Holdings Inc expects USD10m in registered direct offering
M2 - Fri Jan 17, 10:38AM CST
Biotechnology company Bio-Path Holdings Inc (-OTC Markets:BPTH) said on Thursday that it expects to raise about USD10.0m from the sale of units at USD3.00 per unit in a registered direct offering .
Bio-Path Holdings, Inc. to Raise $10 Million in Registered Direct Offering
Business Wire - Thu Jan 16, 7:00AM CST
Bio-Path Holdings, Inc. (OTCQX: BPTH) (Bio-Path), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, announced today that it is raising approximately $10.0 million in a registered direct offering at a price of $3.00 per unit. The entire offering is being sold to two dedicated healthcare funds that are managed by Sabby Management. Each Unit shall consist of one share of Bio-Path common stock, and a warrant to purchase one half (0.5) of a share of Bio-Path common stock. The common stock and warrants shall be immediately separable. The warrants will be exercisable immediately, have a term of five years and an exercise price of $4.74 per share of common stock. After placement agent fees and estimated offering expenses, the Company expects to receive net proceeds of approximately $9.3 million. The offering is expected to close on or about January 22, 2014, subject to customary closing conditions.
Bio-Path Holdings to Present at the Biotech Showcase(TM) 2014 Conference
Business Wire - Mon Jan 06, 9:59AM CST
Bio-Path Holdings, Inc. (OTCQX: BPTH) ("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that Peter Nielsen, President and Chief Executive Officer, will present a company overview at the Biotech Showcase(TM) 2014 Conference in San Francisco, Calif., on Wednesday, January 15, 2014 at 8:00 a.m. Pacific Time.
Preliminary Results from Bio-Path Holdings' Phase I Clinical Trial Presented at the Annual Meeting of the American Society of Hematology (ASH) in New Orleans
Business Wire - Mon Dec 09, 10:20AM CST
Bio-Path Holdings, Inc., (OTCQX: BPTH) ("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, announced that Dr. Jorge Cortes, deputy chair and professor of medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, presented Phase I data from Bio-Path's clinical trial evaluating its lead product candidate, Liposomal Grb-2 (BP-100-1.01), in hematological cancers at the 55th Annual Meeting of the American Society of Hematology (ASH) in New Orleans.
Bio-Path Holdings Reports Third Quarter 2013 Operational and Financial Results
Business Wire - Fri Nov 15, 12:30PM CST
Bio-Path Holdings, Inc., (OTCQX: BPTH) ("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the third quarter ended September 30, 2013.
Data from Bio-Path Holdings Phase I Clinical Trial in Hematological Cancers to be Presented at American Society of Hematology Annual Meeting
Business Wire - Thu Nov 07, 3:03PM CST
Bio-Path Holdings, Inc. (OTCQX: BPTH) ("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that there will be a poster presentation by Dr. Jorge Cortes, deputy chair and professor of medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, at the 55th Annual Meeting of the American Society of Hematology (ASH) in New Orleans. The poster will highlight an assay that was developed to measure inhibition of the disease target protein Grb-2 in patients' peripheral blood samples from the ongoing Phase I trial evaluating the Company's lead compound, Liposomal Grb-2 antisense oligonucleotides in hematological cancers.
Bio-Path Holdings Inc retains Maxim Group LLC as investment banking firm
M2 - Fri Sep 20, 8:00AM CDT
Biotechnology company Bio-Path Holdings Inc (OTC Markets:BPTH) reported on Thursday that it has hired Maxim Group LLC as its financial advisor again for its next phase.
Bio-Path Holdings, Inc. Retains Investment Banking Firm Maxim Group LLC
Business Wire - Thu Sep 19, 8:30AM CDT
Bio-Path Holdings, Inc., (OTCQX: BPTH) ("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has retained Maxim Group LLC, as a financial advisor. Maxim will focus on assisting Bio-Path in its strategies for maximizing shareholder value through its full scope of investment banking services.
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w6k5cg/acute_myelocytic) has announced the addition of the "Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2013" report to their offering. 'Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). Scope - A snapshot of the global therapeutic scenario for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). - A review of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Genzyme Corporation Johnson & Johnson Boehringer Ingelheim GmbH F. Hoffmann-La Roche Ltd. Amgen Inc. Sanofi-Aventis AstraZeneca PLC Eli Lilly and Company GlaxoSmithKline plc Seattle Genetics, Inc. Genentech, Inc. Gilead Sciences, Inc. Daiichi Sankyo Company, Ltd medac GmbH Merck & Co., Inc. Gamida Cell Ltd. Generex Biotechnology Corporation Plexxikon Inc. BioLineRx, Ltd. Bio-Path Holdings, Inc. Millennium Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/w6...myelocytic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Head And Neck Cancer - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5stc2x/head_and_neck) has announced the addition of the "Head And Neck Cancer - Pipeline Review, H2 2013" report to their offering. 'Head And Neck Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Head And Neck Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Head And Neck Cancer. Scope - A snapshot of the global therapeutic scenario for Head And Neck Cancer. - A review of the Head And Neck Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Head And Neck Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Boehringer Ingelheim GmbH Eli Lilly and Company Inovio Biomedical Corporation Gilead Sciences, Inc. GenVec, Inc. Piramal Healthcare Limited Bio-Path Holdings, Inc. Millennium Pharmaceuticals, Inc. Novartis AG Daewoong Pharmaceutical Co., Ltd. Taiho Pharmaceutical Co., Ltd. Takara Holdings Inc. Cell Therapeutics, Inc. CEL-SCI Corporation Advaxis, Inc. Bionomics Limited Northwest Biotherapeutics, Inc. Oncolytics Biotech Inc. Curis, Inc. Transgene SA Panacea Biotec Limited and many more.... For more information visit http://www.researchandmarkets.com/research/5s...d_and_neck About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snxwsx/acute_lymphocytic) has announced the addition of the "Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2013" report to their offering. 'Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). Scope - A snapshot of the global therapeutic scenario for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). - A review of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Amgen Inc. Sanofi-Aventis Seattle Genetics, Inc. MedImmune LLC medac GmbH Gamida Cell Ltd. Bio-Path Holdings, Inc. Millennium Pharmaceuticals, Inc. Novartis AG Pfizer Inc. Incyte Corporation 4SC AG IMMUNOMEDICS, INC Ariad Pharmaceuticals, Inc. OncoVista Innovative Therapies, Inc. Jazz Pharmaceuticals, Inc. Portola Pharmaceuticals, Inc. Mundipharma International Limited MorphoSys AG Lipoxen PLC and many more... For more information visit http://www.researchandmarkets.com/research/sn...ymphocytic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Myelodysplastic Syndrome - Pipeline Review, H2 2013
M2 - Mon Sep 09, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7p96jv/myelodysplastic) has announced the addition of the "Myelodysplastic Syndrome - Pipeline Review, H2 2013" report to their offering. 'Myelodysplastic Syndrome - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Myelodysplastic Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome. Scope - A snapshot of the global therapeutic scenario for Myelodysplastic Syndrome. - A review of the Myelodysplastic Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Myelodysplastic Syndrome pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Amgen Inc. Athersys, Inc. GlaxoSmithKline plc Daiichi Sankyo Company, Ltd medac GmbH Merck & Co., Inc. Dainippon Sumitomo Pharma Co., Ltd. Gamida Cell Ltd. Bio-Path Holdings, Inc. Millennium Pharmaceuticals, Inc. Novartis AG Pfizer Inc. Sunesis Pharmaceuticals, Inc. SuperGen, Inc. Teva Pharmaceutical Industries Limited Cyclacel Pharmaceuticals Inc. Celgene Corporation Incyte Corporation 4SC AG Celldex Therapeutics, Inc. Marshall Edwards, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/7p...dysplastic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bio-Path Holdings Reports Second Quarter 2013 Operational and Financial Results
Business Wire - Thu Aug 15, 8:30AM CDT
Bio-Path Holdings, Inc., (OTCQX: BPTH) ("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the second quarter ended June 30, 2013.
Bio-Path Holdings' Liposomal Delivery Technology Achieves Major Milestone in Development of Antisense Therapeutics
Business Wire - Fri Aug 09, 8:30AM CDT
Bio-Path Holdings, Inc. (OTCQX: BPTH) ("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that a scientific assay has confirmed that its lead product candidate BP-100-1.01 (Liposomal Grb-2) inhibits the disease-causing target protein in patients with blood cancers. The assay was applied to patient samples taken from Bio-Path's Phase I clinical trial which is evaluating Liposomal Grb-2 in blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS). This discovery is a significant milestone in the development of Bio-Path's liposomal delivery technology and the specific data from this testing is planned to be reviewed at the Annual Society of Hematology (ASH) meeting in December by Jorge Cortes, M.D., Professor and Deputy Chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center (MD Anderson Cancer Center).
Therapeutic Report for Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
M2 - Tue Aug 06, 5:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5sqnpw/acute_lymphocytic) has announced the addition of the "Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2012" report to their offering. This report provides an overview of the acute lymphocytic leukemia therapeutic pipeline. It provides information on the therapeutic development for acute lymphocytic leukemia complete with latest updates, and special features on late-stage and discontinued projects. The document is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for acute lymphocytic leukemia. - A review of the acute lymphocytic leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the acute lymphocytic leukemia pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for acute lymphocytic leukemia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players with the most promising pipeline. - Devise corrective measures for pipeline projects by understanding acute lymphocytic leukemia pipeline depth and focus of acute lymphocytic leukemia therapeutics. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Acute Lymphocytic Leukemia Overview Therapeutics Development An Overview of Pipeline Products for Acute Lymphocytic Leukemia Companies Involved in Acute Lymphocytic Leukemia Therapeutics Development Drug Profiles Featured News & Press Releases Appendix Companies Mentioned (40) Including: - 4SC AG - Ariad Pharmaceuticals - Bio-Path Holdings - Bristol-Myers Squibb Company - CanBas Co - Exelixis - F. Hoffmann-La Roche - Genzyme Corporation - Hana Biosciences - Incyte Corporation - Jazz Pharmaceuticals - KaloBios Pharmaceuticals - Lentigen Corporation - Millennium Pharmaceuticals - MorphoSys AG - Mundipharma International - Novartis AG - Onconova Therapeutics - Oryzon - Pfizer - Proacta - Sigma-Tau Pharmaceuticals - SuperGen - SymbioTec GmbH - Threshold Pharmaceuticals - TopoTarget A/S - Tragara Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/5s...ymphocytic
Bio-Path Holdings Initiates Development of Liposomal Grb-2 for Triple Negative and Inflammatory Breast Cancers
Business Wire - Mon Jul 22, 8:30AM CDT
Bio-Path Holdings, Inc., (OTCQX:BPTH) ("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it is initiating preclinical testing of its lead product candidate, BP-100-1.01 (Liposomal Grb-2), into two additional indications: triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates. Bio-Path is currently evaluating Liposomal Grb-2 in a Phase I clinical trial as a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS). The clinical trial and research is being conducted at The University of Texas MD Anderson Cancer Center (MD Anderson Cancer Center).
(0)
(0)Bio-Path Holdings (BPTH) Stock Research Links
Scroll down for more posts ▼